<DOC>
	<DOCNO>NCT00745771</DOCNO>
	<brief_summary>Multiple-dose , double-blind , double-dummy , parallel , randomized , placebo active control study pharmacokinetics Diractin® well safety efficacy muscle soreness exercise .</brief_summary>
	<brief_title>Multiple Dose , Double-Blind , Placebo Active Controlled Study Pharmacokinetics Diractin® Well Safety Efficacy Treatment Muscle Soreness</brief_title>
	<detailed_description />
	<mesh_term>Myalgia</mesh_term>
	<criteria>Understands nature provision study Have inform study investigator give sign date informed consent prior participation Muscle soreness pain score least 3 10 point categorical pain scale 1216h exercise Male female subject Age 1855 year Subjects good health determine Investigator Woman childbearing potential use reliable method contraception low failure rate ( i.e . le 1 % per year ) , e.g . implant , injectables , combine oral contraceptive , reliable intrauterinedevices , vasectomised/ infertile partner surgically sterile ( uterus remove tube tie ) postmenopausal ( least 2 year without period ) 4.2.1 General Exclusion Criteria Investigator team member involve directly indirectly conduct clinical trial Subjects inmates psychiatric ward , prison , state institution Participation another clinical trial within last 30 day study Not willing refrain expose target area treatment excessive ultraviolet light ( solar radiation solarium ) Pregnancy lactation 4.2.2 Medical History Related Exclusion Criteria History dermal allergic reaction Known hypersensitivity allergy ( include photoallergy ) NSAID´s include ketoprofen , ingredient use pharmaceutical product Alcohol drug abuse Malignancy within past 2 year Skin lesion , dermatological disease tattoo treatment area Major surgery 3 month enrolment NSAID idiosyncrasy Impaired haematopoesis coagulation Gastric duodenal ulcer gastrointestinal bleeding Systemic lupus erythematodes , mixed connective tissue disease Major heart disease / uncontrolled hypertension Hepatic failure ALT and/or AST &gt; 2.0 ULN Renal failure serum creatinine level &gt; 1.5 milligrams/deciliter ( mg/dL ) Varicosis , thrombophlebitis vascular disorder low extremity Major traumatic lesion ( e.g . fracture , tendon muscle rupture ) musculosceletal system lower limbs HIV Infection Hepatitis B C Asthma bronchiale Blood donation one month screening study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>Diractin®</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>exercise</keyword>
</DOC>